Targeting costimulatory molecules to improve antitumor immunity

Daria Capece, Daniela Verzella, Mariafausta Fischietti, Francesca Zazzeroni, Edoardo Alesse*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations

Abstract

The full activation of T cells necessitates the concomitant activation of two signals, the engagement of T-cell receptor by peptide/major histocompatibility complex II and an additional signal delivered by costimulatory molecules. The best characterized costimulatory molecules belong to B7/CD28 and TNF/TNFR families and play crucial roles in the modulation of immune response and improvement of antitumor immunity. Unfortunately, tumors often generate an immunosuppressive microenvironment, where T-cell response is attenuated by the lack of costimulatory molecules on the surface of cancer cells. Thus, targeting costimulatory pathways represent an attractive therapeutic strategy to enhance the antitumor immunity in several human cancers. Here, latest therapeutic approaches targeting costimulatory molecules will be described.

Original languageEnglish (US)
Article number926321
JournalJournal of Biomedicine and Biotechnology
Volume2012
DOIs
StatePublished - 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Health, Toxicology and Mutagenesis

Fingerprint

Dive into the research topics of 'Targeting costimulatory molecules to improve antitumor immunity'. Together they form a unique fingerprint.

Cite this